Thursday, February 10, 2022 12:05:24 AM
https://ir.humanigen.com/English/news/news-details/2022/Humanigen-Launches-Managed-Access-Program-for-Lenzilumab/default.aspx
Lenzilumab is available via LenzMAP in the following 17 countries:
Austria
Bulgaria
Croatia
Cyprus
Denmark
Estonia
France
Greece
Ireland
Lithuania
Luxembourg
Netherlands
Portugal
Spain
Sweden
Switzerland
United Kingdom
LenzMAP will enable access to lenzilumab on a case-by-case basis for hospitalized patients with COVID-19 for whom the treating physician deems there are no suitable alternatives and where regulations allow.
“We are pleased to be working with Clinigen to provide access to lenzilumab on a patient-by-patient basis in the United Kingdom and certain other European countries,” said Timothy E. Morris, COO and CFO of Humanigen. “While we continue to pursue our development program for lenzilumab and seek to attain appropriate authorizations or approvals for its potential commercial use in the United States, European Union and United Kingdom, LenzMAP will enable Humanigen to respond to requests from healthcare professionals for access to lenzilumab to treat certain hospitalized patients where allowed by local regulations.”
Clinigen will manage key elements of LenzMAP, including regulatory oversight, reimbursement, logistics, and access management.
“We are proud to partner with Humanigen in offering this potential treatment option for certain hospitalized patients with COVID-19 in the UK and across Europe. LenzMAP underscores Clinigen’s strength in partnering with biotechnology companies to provide services that enable quicker and broader access to critical medicines,” commented Pete Belden, Executive Vice President Services Division, Clinigen.
Clinigen currently oversees more than 161 similar managed access programs for other companies and has access to over 20,000 healthcare providers in 5,000 hospitals across more than 120 countries.
“As we move from the pandemic stage to the endemic stage of COVID-19, healthcare professionals continue to see vaccinated and unvaccinated patients alike presenting with elevated inflammatory markers,” stated Andrea Aroldi, MD, San Gerardo Hospital (Monza, Italy). “Now that lenzilumab is available on a compassionate-use/named-patient basis in certain European countries, physicians have available an additional treatment option, an immunomodulator, in their armamentarium of therapies in the fight against COVID-19.”
Healthcare professionals may obtain details about LenzMAP™ by calling the Clinigen customer service team at +44 (0) 1932 824100, e-mailing MedicineAccess@clinigengroup.com, or going online at www.clinigendirect.com.
Patients seeking medical information should contact their physician.
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM